Dyadic International, Inc.
Dyadic International, Inc.
Dyadic International, Inc.
DYAI
DYAI
Nasdaq
Health Services
Medical/Nursing Services
1.19
USD
-0.02
-1.65%
Kapalı: 07-24 20:00 (UTC+0)
1.19
USD
+0.0559
+4.70%
Seans sonrası: 07-25 00:00 (UTC+0)

DYAI Temel İstatistikler

YÜKSEK
1.26
Açık
1.21
Hacim
105.18K
Düşük
1.12
Önceki Kapanış
1.21
İşlem Değeri
125.54K
52H En Yüksek
1.60
Göreceli Hacim
0.371
Dalgalanma (%)
11.49%
52H En Düşük
0.65
Devir Oranı
0.29%
Piyasa Değeri
43.36M
F/K (TTM)
--
F/K (Yıllık)
--
GD/DD
-106.35
F/S
11.39
Hisse Başına Kazanç (EPS)
-0.214
Temettü (TTM)
0
Temettü Verimi
0.00%
Dolaşımdaki hisseler
36.43M
Para Birimi
USD

DYAI Fiyat Performansı

7 gün
30 gün
90 gün
180 gün
Yıl başından bugüne
1 Yıl
DYAI Para Akışı Dağılımı
DYAI Günlük Açığa Satış Hacmi
DYAI Short Interest Geçmişi
As of 2026-07-26, the Dyadic International, Inc. (DYAI) stock price today is 1.19. Based on this price, the company has a market capitalization of $43.36M, with a P/E ratio of --. On 2026-07-26, DYAI traded between 1.12 and 1.26. Today’s stock price is 6.25% above the daily low and 5.56% below the daily high, placing DYAI orta seviyesine yakın its most recent trading range. Trading volume currently stands at 105.18K, compared with an average daily volume of 283.91K. This suggests that trading activity is olağan seviyesinin belirgin şekilde altında than usual. Over the past year, Dyadic International, Inc. shares have traded between 0.65 and 1.60. At today’s price, DYAI is 83.08% above its 52-week low and 25.63% below its 52-week high.
Şirket adı
Dyadic International, Inc.
Sektör
Health Services
Endüstri
Medical/Nursing Services
Borsalar
Nasdaq
Çalışan Sayısı
5
Lot Büyüklüğü
100
Resmî web sitesi
Para Birimi
USD
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.

DYAI FAQ

Ara
Daha fazla